Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 15Terminated 7Recruiting 4Unknown 3Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Burkitt Lymphoma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Leukemia, Biphenotypic, Acute 2Skin Neoplasms 1Shwachman-Diamond Syndrome 1Recurrence 1Primary Immunodeficiency Diseases 1Oropharyngeal Neoplasms 1Neutropenia, Severe Congenital, Autosomal Recessive 3 1Myelodysplastic Syndromes 1Melanoma 1Macrophage Activation Syndrome 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Lymphohistiocytosis, Hemophagocytic 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Histiocytosis, Langerhans-Cell 1Histiocytosis 1Hemoglobinopathies 1Drug-Related Side Effects and Adverse Reactions 1Down Syndrome 1Cranial Nerve Diseases 1Colitis 1

Interventions

Dexamethasone 115Lenalidomide 74daratumumab 57Bortezomib 52carfilzomib 41Calcium Dobesilate 36pomalidomide 35Cyclophosphamide 26isatuximab 23belantamab mafodotin 22Specimen Handling 20Biopsy 20Magnetic Resonance Spectroscopy 17dexamethasone acetate 13dexamethasone 21-phosphate 13auricularum 12ixazomib 11iberdomide 11fludarabine 11elotuzumab 11selinexor 10Melphalan 10fludarabine phosphate 8talquetamab 7X-Rays 7trametinib 6nirogacestat 6venetoclax 5Thalidomide 5Nuclear Medicine Department, Hospital 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Multiple Myeloma × Methylprednisolone × Clear all
NCT05704049 2025-12-29

IZALCO

Sanofi

Phase 2 Active not recruiting
118 enrolled
Plasma cell

Multiple Myeloma

NCT04270409 2025-12-12

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Sanofi

Phase 3 Active not recruiting
337 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡